Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancerReportar como inadecuado




Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

(2015)ONCOTARGET.7(3).p.3068-3083 Mark abstract Somatic mutations found within the tyrosine kinase domain (TKD) of the human epidermal growth factor (HER) family of receptors have been implicated in the development and progression of non-small cell lung cancer (NSCLC). However, no conclusive reports have described pathogenic mutations in kinase-impaired HER3. Here, we report a case of an advanced chemotherapy-resistant NSCLC, harboring a novel HER3(V855A) somatic mutation homologous to the EGFR(L858R)activating mutation. Co-expression of HER3(V855A) and wild-type HER2 enhances ligand-induced transformation of murine and human cell lines, while HER-targeted inhibitors potently suppress mutant HER3 activity. Consistent with these observations, in silico computational modeling predicts that mutant V855A alters the kinase domain and c-terminal end of the HER3 protein. Taken together, these findings provide a basis for the clinical exploration of targeted therapies in HER3 mutant NSCLC and by extrapolation, in other cancers that more frequently carry somatic HER3 mutations.

Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8515597



Autor: Ijeoma Umelo, Amir Noeparest, Gang Chen, Marleen Renard, Caroline Geers, Johan Van Steenkiste, Philippe Giron, Olivier De Wever ,

Fuente: https://biblio.ugent.be/publication/8515597



DESCARGAR PDF




Documentos relacionados